PO-058 Cisplatin, Fluorouracil, Docetaxel in Head and Neck Carcinoma: real data of induction chemotherapy
Filipa Ferreira Pereira(IPO Porto), Cláudia Vieira, José Dinis(Instituto Português de Oncologia Francisco Gentil), Isabel Azevedo(Instituto Português de Oncologia Francisco Gentil), L. Castro Oliveira(IPO Porto)
Cited by 0
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Chronic Inflammation in Obesity and the Metabolic Syndrome
|Mediators of Inflammation|2010|1.2k
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE
|Journal of Clinical Oncology|2011|221
Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial
|Annals of Oncology|2017|90
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
|Cancer Chemotherapy and Pharmacology|2014|87